Ping An Biomedical Co. Ltd. Ordinary Shares (PASW)
FairStock Score: 45/100 — MIXED
Key Financials
| Current Price | $4.76 |
| Market Cap | $21M |
| P/E Ratio | -79.33 |
| ROE | -11.35% |
| Dividend Yield | —% |
| Sector | Consumer Cyclical |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
I look for businesses with durable advantages, honest accounting, and a margin of safety. Ping An Biomedical operates in apparel supply-chain management, yarns, textiles, garments, property, and warehousing. That is a tough, cyclical set of businesses, and the figures show a company under pressure. The stock closed at $0.13 on 2026-10-13, giving a market cap of $21.3M. FairStock's P/E is -2.10, so trailing earnings are negative; its ROE is -11.35% and ROCE is -8.86%. Those are not the marks of a high-quality compounder. Debt-to-equity of 0.13 is modest, which helps, but the Altman Z-score of 0.83 is in distress territory and the Piotroski F-score is only 3/9. FairStock's P/B is 1.40, meaning investors pay a premium to book for a loss-making concern. The 52-week range of $0.11 to $0.80 shows severe price erosion. Revenue and profit growth are N/A, and the Lynch category is none because there are only 0 years of filed results, three needed; I cannot assess a multi-year growth trajectory. With only 7 employees reported, the operating structure may rely heavily on subsidiaries or contractors. A moat is hard to identify in textile manufacturing and supply-chain services, where competition is intense and pricing power limited. The FairStock Score of 45/100 suggests average-to-weak overall. Unless earnings and returns turn positive, book value may not be a reliable floor. I would need multiple years of clean filings showing improving margins, positive ROCE, and a stronger balance sheet before calling this a value opportunity.
In plain English: Ping An Biomedical is an apparel supply-chain company that also makes yarn, textiles and garments and owns some property and warehousing. It is losing money, has weak financial health, and has no multi-year track record in the data. At $0.13 a share, the price is near the low end of its 52-week range, but because the company is not profitable it does not look like a proven bargain.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer